Zhao, X., Li, X.Y., Zhou, L.L., Ni, J., Yan, W.Y., Ma, R., et al. (2018) LncRNA HOXA11-AS Drives Cisplatin Resistance of Human LUAD Cells via Modulating miR-454-3p/Star3. Cancer Science, 109, 3068-3079.
https://doi.org/10.1111/cas.13764

has been cited by the following article:

• TITLE: Research on HOXA11-AS in Malignant Tumors

  AUTHORS: Juncheng Guo, Jinfang Zheng, Yijun Yang

  KEYWORDS: Long Non-Coding RNA, HOXA11-AS, Malignant Tumor

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.1, January 14, 2021

  ABSTRACT: Long-chain non-coding RNA HOXA11 antisense RNA (HOXA11-AS) is a kind of lncRNA discovered in recent years. Long-chain non-coding RNA (LncRNA) is an important regulatory factor of protein-coding genes, especially the disorder of LncRNA in more and more diseases which are found, including cancer. HOXA11-AS was first discovered in mouse embryo cDNA library using probes, and then it was discovered by scholars and played an important role in human cervical cancer, gastric cancer, glioma and other malignant tumor cells. Overexpression of HOXA11-AS has been found to promote cell proliferation, migration and tumor invasion, and has a carcinogenic effect. HOXA11-AS can promote tumor proliferation, metastasis and other malignant biological behaviors by interacting with miRNA and EZH2 protein, and is considered to be carcinogenic lncRNA. The discovery of HOXA11-AS provides new ideas for tumor prevention and treatment.